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Stephen Landy1, Sagar Munjal2*, Elimor Brand-Schieber2 and Alan M. Rapoport3Abstract
Background: DFN-11, a 3 mg sumatriptan subcutaneous (SC) autoinjector for acute treatment of migraine, has not
been assessed previously in multiple attacks. The objective of this study was to evaluate the efficacy, tolerability,
and safety of DFN-11 in the acute treatment of multiple migraine attacks.
Methods: This was an 8-week open-label extension of multicenter, randomized, double-blind, placebo-controlled
US study. Subjects averaging 2 to 6 episodic migraine attacks per month were randomized to DFN-11 or placebo to
treat a single attack of moderate-to-severe intensity and then entered the extension study to assess the efficacy,
tolerability, and safety of DFN-11 in multiple attacks of any pain intensity.
Results: Overall, 234 subjects enrolled in the open-label period, and 29 (12.4%) discontinued early. A total of 848
migraine episodes were treated with 1042 doses of open-label DFN-11 and subjects treated a mean (SD) of 3.9 (2.3)
attacks. At 2 h postdose in attacks 1 (N = 216), 2 (N = 186), 3 (N = 142) and 4 (N = 110), respectively, pain freedom
rates were 57.6%, 64.6%, 61.6%, and 66.3%; pain relief rates were 83.4%, 88.4%, 84.1%, and 81.7%; most bothersome
symptom (MBS)-free rates were 69.0%, 76.5%, 77.7%, and 74.7%; nausea-free rates were 78.1%, 84.6%, 86.5%, and 85.
7%; photophobia-free rates were 75.3%, 76.4%, 72.3%, and 77.5%; and phonophobia-free rates were 75.2%, 77.5%,
73.6%, and 76.0%. Overall, 40.6% (89/219) of subjects reported treatment-emergent adverse events (TEAE), the most
common of which were associated with the injection site: swelling (12.8%), pain (11.4%), irritation (6.4%), and bruising
(6.4%). Most subjects (65.2%, 58/89) had mild TEAEs; severe TEAEs were reported by 1 subject (treatment-related jaw
tightness). Five subjects (2.1%) discontinued due to adverse events, which included mild throat tightness (n = 2),
moderate hernia pain (n = 1), moderate hypersensitivity (n = 1), and 1 subject with mild nausea and moderate injection
site swelling. There were no serious TEAEs and no new or unexpected safety findings.
Conclusion: DFN-11 was effective, tolerable, and safe in the acute treatment of 4 migraine attacks over 8 weeks,
with consistent responses on pain and associated symptoms. Most TEAEs were mild, with a very low incidence of
triptan-related TEAEs. DFN-11 is potentially an effective and safe alternative for the acute treatment of migraine.
Trial registration: ClinicalTrials.gov, NCT02569853. Registered 07 October 2015.
Keywords: Low-dose sumatriptan, Multi-attack acute subcutaneous sumatriptan, Consistency of effect* Correspondence: smunjal@drreddys.com
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Migraine is a painful, disabling, and, for most patients, life-
long disease [1, 2]. Although migraineurs rate consistent re-
lief with few side effects among the most desirable attributes
of an acute migraine medication [3–6], and clinical trial
guidelines recommend assessment of the consistency of re-
sponse to acute medications in multiple-attack studies [7],
the effectiveness of acute medications across multiple at-
tacks is not frequently evaluated in clinical trials. Yet the
utility of acute treatments depends, in part on their ability to
be effective, tolerable, and safe over the long-term [8]; incon-
sistent relief is an important reason for dissatisfaction with
acute therapy [3]. Moreover, confidence that an intervention
will reliably relieve migraine pain and associated symptoms
is a predictor of adherence to acute therapy [9].
Single-attack studies are not designed to evaluate
inter-attack variability of treatment outcomes [10].
DFN-11 (Zembrace® SymTouch®, Promius Pharma,
Princeton, NJ) is a low-dose (3 mg) SC sumatriptan
injection, supplied as a single-dose, ready-to-use, disposable
autoinjector. Compared with the 6-mg SC dose of
sumatriptan (Imitrex®, GlaxoSmithKline, Research Triangle
Park, NC), DFN-11 has less sumatriptan per 0.5-mL dose
(3 mg vs 6 mg) [11, 12]. Other research has shown that
DFN-11 provides relief of migraine pain and associated
symptoms similar to a 6-mg SC dose of sumatriptan, with
fewer triptan sensations and no reports of chest pain, in
adults with rapidly-escalating migraine attacks [13]. Subse-
quent work in episodic migraine found that DFN-11 was sig-
nificantly more effective than placebo on pain-free and pain
relief outcomes from 30 min through 2 h postdose and con-
firmed the low incidence of TEAEs and triptan sensations
[14]. The objective of this study was to evaluate the efficacy,
tolerability, and safety of DFN-11 in the acute treatment of
multiple migraine attacks in adults with episodic migraine.
Methods
Ethics
This was a randomized, double-blind, placebo-controlled study
with an open-label extension to evaluate the efficacy, tolerabil-
ity, and safety of DFN-11 in adults with episodic migraine at
16 US study centers. The data from the double-blind portion
of the study have been presented elsewhere [14]. The protocol
was approved by the institutional review boards at each study
site, and the study conduct complied with good clinical practice
and the ethical principles in the Declaration of Helsinki. Prior
to screening, investigators explained the nature of the study
and obtained informed consent from subjects. The study is
registered at ClinicalTrials.gov (https://clinicaltrials.gov/; Identi-
fier NCT02569853).
Subjects
Subjects included adult males and females (18–65 years
of age) with a history of episodic migraine with orwithout aura (defined by the Second Edition of Inter-
national Classification of Headache Disorders (ICHD-2)
[15]). They had to have 2 to 6 migraine attacks per
month for at least the previous 12 months, with no more
than 14 headache days per month and a minimum of
48 h of headache-free time between attacks. Subjects
had to meet all inclusion and exclusion criteria to be in-
cluded in the study.Treatments
DFN-11 (equivalent to 3 mg sumatriptan base in 0.5 mL
sterile solution) was provided as an SC injection in a
29-gauge needle-based autoinjector.Study procedures
This study included site visits for screening, baseline/
randomization, end double-blind/begin open-label, week
4±3 days, and week 8±3 days/early termination.
During screening, subjects provided informed consent
and staff verified inclusion and exclusion criteria. Subjects
were given an electronic diary (eDiary) and instructions
on how to complete it, medical and migraine histories
were taken, and a physical examination was performed.
At baseline, inclusion and exclusion criteria were
re-verified, and medical and treatment histories and
physical examinations (including laboratory and vital
sign measurements) were repeated. Subjects were ran-
domized (1:1) to receive DFN-11 or placebo via SC auto-
injector in a double-blinded fashion to treat 1 migraine
attack. Study centers used an Interactive Web Response
System to assign drug kits (ie, labeled cartons containing
2 individually labeled autoinjectors) at scheduled and
unscheduled visits as needed.
At the conclusion of the double-blind treatment
period, subjects were re-examined, and vital signs mea-
surements were repeated. Study staff assessed eligibility
for continuing into an open-label period, and eligible
subjects entered an 8-week open-label period. During
this period, subjects received DFN-11 for 8 weeks and
were instructed to treat multiple attacks within 1 h of
migraine pain onset at any level of pain intensity. If sub-
jects did not experience sufficient relief 2 h after taking
the first dose of study medication, they were allowed a
second dose of study medication or rescue medication
for the same attack. No more than 2 doses of study
medication could be taken in any 24-h period. Rescue
medications could include prescription and nonprescrip-
tion drugs (eg, NSAIDs, other acute migraine medica-
tions, vitamins, herbal/dietary supplements).
Adverse events (AEs) were monitored from the time
subjects gave informed consent; physical examinations,
vital sign measurements, ECGs, and laboratory assess-
ments were performed at designated site visits.
Landy et al. The Journal of Headache and Pain  (2018) 19:70 Page 3 of 8Assessments
In the open-label period, efficacy was assessed for each
of the first 4 reported migraine attacks. Efficacy end-
points included the percentage of subjects who had
pain-freedom, pain relief, and absence of their most
bothersome symptom (MBS) at 10, 15, 20, 30, 60, 90,
and 120 min, and the percentage of subjects who were
free from nausea, photophobia, and phonophobia at 2 h
postdose. The percentage of subjects with sustained pain
freedom from 2 to 24 h postdose was also assessed.
Pain freedom was defined as a reduction in migraine
pain from a predose rating of moderate (Grade 2) or se-
vere (Grade 3) pain to none (Grade 0). Pain relief was
defined as a reduction in migraine pain from predose
rating of severe (Grade 3) or moderate (Grade 2) to mild
pain (Grade 1) or none (Grade 0), or from mild pain
(Grade 1) to none (Grade 0). Absence of MBS was de-
fined as absence of the symptom chosen as most bother-
some from among nausea, photophobia, or phonophobia
at predose. Sustained pain freedom was defined as
pain-free at 2 h postdose with no use of rescue medication
or additional study medication and no recurrence of head-
ache pain within 2 to 24 h postdose.
Safety and tolerability were assessed throughout the
open-label period. Tolerability included the percentage
of subjects with treatment-emergent AEs (TEAEs).
Safety endpoints included the percentage of subjects
with serious AEs (SAEs), as well as those with changes
in vital signs or ECGs. Safety parameters included con-
comitant medication review; physical examinations;
pregnancy tests in females; measurement of vital signs
(sitting systolic and diastolic blood pressure, pulse rate,
and body temperature); clinical laboratory examination
(hematology, chemistry, and urinalysis); urine drug
screen; and 12-lead ECG.
Statistics
All data processing, summarization, and analyses were per-
formed using SAS® software, Version 9.2. Adverse events
were classified using the Medical Dictionary for Regulatory
Activities (MedDRA) dictionary, Version 18.0. Concomi-
tant medications were coded using the World Health
Organization Drug Dictionary Enhanced (WHODDE), ver-
sion Mar2015 further coded against Anatomic Therapeutic
Chemical (ATC) classification.
Subjects randomized in the double-blind period com-
prised the population for subject disposition and
baseline summaries. The open-label efficacy analyses in-
cluded all open-label subjects who received at least 1
dose of active study medication and recorded at least 1
postdose efficacy data point in the open-label period.
The open-label safety analysis included all open-label
subjects who received at least 1 dose of study
medication.Unless noted otherwise, a last observation carried for-
ward (LOCF) imputation method was applied to pain in-
tensity and the presence of nausea, photophobia, and
phonophobia. Baseline data were not carried forward,
and only valid data from postbaseline assessments col-
lected before the 2-h postdose time point were carried
forward to impute the next missing assessment up to
the 2-h postdose time point. Time points beyond 2 h
postdose were not carried forward.
The analysis of safety was based on data from all ran-
domized subjects who received at least 1 dose of study
medication. The efficacy analyses were based on data
captured in the eDiary for migraine attacks treated. Post-
dosing assessments were collected in real-time. Change
from baseline was defined as the postbaseline value
minus the predose value, and calculations were based on
nonmissing data. Baseline for safety assessments was
defined as the last assessment before receiving the first
dose of study medication in the double-blind period.
Results
Disposition
A total of 16 US study sites participated and randomized
subjects into the study. The duration of the study, from
the first subject’s enrollment until the last subject’s com-
pletion, was 618 days (21 September 2015 through 30
May 2017).
As shown in Fig. 1, 392 subjects were screened, 268
(68.4%) were randomized, 234 (87.3% of those random-
ized) completed the double-blind treatment period and
enrolled in the open-label extension. A total of 205
(87.6% of those who enrolled) completed the open-label
extension (Table 1).
Of the 234 subjects who entered the open-label exten-
sion, 216 (92.3%) treated at least 1 attack, 186 (79.5%)
treated at least 2 attacks, 142 (60.7%) treated at least 3 at-
tacks, and 110 (47.0%) treated 4 attacks or more. A total
of 29 subjects (12.4%) discontinued: 9 (3.8%) were lost to
follow-up, 7 (3.0%) withdrew consent, and 5 (2.1%) dis-
continued due to AEs.
Demographics
Most subjects were female (85.4%) and white (75.7%),
with a mean (SD) age of 41.0 (12.4) years. Mean (SD)
weight was 84.4 (23.7) kg and mean (SD) BMI was 30.6
(8.6) kg/m2.
Exposure
Over the course of the 8-week open-label extension,
subjects used 1042 doses of DFN-11 to treat 848 mi-
graine attacks, and they treated a mean (SD) of 3.9 (2.3)
attacks per subject. In attacks 1, 2, 3, and 4, respectively,
a second dose of DFN-11 (allowed after the completion
of the 2-h efficacy assessments) was used by 19.9% (43/
Fig. 1 Disposition of subjects
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110) of subjects.
Efficacy
At 2 h after DFN-11 treatment, the percentages of subjects
who were pain-free in attacks 1, 2, 3, and 4, respectively,
were 57.6%, 64.6%, 61.6%, and 66.3%. The 2-h pain relief re-
sponse rates were 83.4% for attack 1, 88.4% for attack 2,
84.1% for attack 3, and 81.7% for attack 4. The percentageTable 1 Subject disposition
Screened
Double-blind Treatment Period DFN-11
Randomized 131
Completed 111
Discontinued 20
Open-label Treatment Period
(All active DFN-11)
Treatment Received During DB, Prior to OL
DFN-11
Enrolled 111a
Completed 96a
Discontinued 15a
Reasons for discontinuation Discont. During DB Discont. During OLE
Adverse event 2 3
Lost to follow-up 3 8
Protocol violation 1 1
Withdrew consent 3 2
Investigator decision 1 0
Other 10 1
Total discontinued 20 15
DB double-blind treatment period, OLE open-label extension period
aTreatment group reflects OLE subjects’ assignment during the DB periodof subjects with 2-h postdose absence of MBS in attacks 1
to 4, respectively, was 69.0%, 76.5%, 77.7%, and 74.7%.
Pain-free, pain relief, and MBS responses to DFN-11 for the
4 individual attacks, as well as for the attack treated with
DFN-11 in the double-blind period, are presented in Fig. 2.
For freedom from the associated symptoms of mi-
graine, Fig. 3 shows that in attacks 1, 2, 3, and 4, respect-
ively, 78.1%, 84.6%, 86.5%, and 85.7% subjects were free
of nausea; 75.3%, 76.4%, 72.3%, and 77.5% were free of392
Placebo Total
137 268
123 234
14 34
Period Overall
Placebo
123a 234
109a 205
14a 29
a Discont. During DB Discont. During OLEa OLE Total DB + OLE
0 2 5 7
3 1 9 15
1 3 4 6
2 5 7 12
1 2 2 4
7 1 2 19
14 14 29 63
Fig. 2 Pain freedom, pain relief, and absence of the most bothersome symptom (MBS) at 2 h after treatment with DFN-11 in the open-label and
double-blind study periods
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free of phonophobia.
Rates of sustained pain freedom from 2 to 24 h post-
dose in attacks 1, 2, 3, and 4, respectively, were 83.9%
(78/93), 76.5% (65/85), 81.3% (52/64), and 77.8% (42/54).
Use of a second dose or rescue medication
The percentage of subjects who took a second dose of
study medication, rescue medication, or both, in the 2 to
24 h postdose in attacks 1, 2, 3, and 4, respectively, was
19.4% (42/216), 21.0% (39/186), 16.9% (24/142), and
25.5% (28/110).
Tolerability and safety
During the open-label period, 40.6% (89/219) of subjects
reported TEAEs. The most common TEAEs wereFig. 3 Freedom from nausea, photophobia, and phonophobia at 2 h afterinjection site swelling (12.8%), injection site pain
(11.4%), injection site irritation (6.4%), and injection site
bruising (6.4%), as shown in Table 2. Most subjects
(65.2%, 58/89) reported a maximum TEAE severity of
mild; 24.7% (22/89) reported moderate TEAEs. Eight
subjects did not have severity assigned. A single subject
reported 10 occurrences of severe joint stiffness (de-
scribed as injection-related jaw tightness) that was con-
sidered definitely related to the study medication. The
relationship to DFN-11 was considered by the investi-
gator as definite in 26.9% (59/219) of subjects and
probable in 6.4% (14/219) of subjects. Five subjects
(2.1%) discontinued due to AEs that included mild
throat tightness (n = 2); moderate hernia pain (n = 1);
moderate hypersensitivity (n = 1); and mild nausea and
moderate injection site swelling (n = 1).treatment with DFN-11
Table 2 Treatment-emergent adverse events occurring in ≥1%
of subjects treated with DFN-11
(N = 219)
n (%)
Subjects with ≥1 TEAE 89 (40.6)
Injection site
Bruising 14 (6.4)
Erythema 8 (3.7)
Induration 6 (2.7)
Irritation 14 (6.4)
Pain 25 (11.4)
Swelling 28 (12.8)
Nausea 6 (2.7)
Chest discomfort 6 (2.7)
Sinusitis 3 (1.4)
Upper respiratory tract infection 7 (3.2)
Burning sensation 3 (1.4)
Dizziness 4 (1.8)
Paresthesia 3 (1.4)
Somnolence 3 (1.4)
TEAE treatment-emergent adverse event
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and no notable shifts in chemistry or hematology param-
eters, vital signs, or physical examinations; no clinically
significant values on these parameters were reported
during the study.Injection site reactions
The most common TEAEs overall were associated with
the injection site: swelling (12.8%, 28/219); pain (11.4%,
25/219); and irritation and bruising (both 6.4%, 14/219
each). At least 1 injection site reaction was reported by
27.4% (60/219) of subjects overall, and rates were 19.9%
(43/216) in attack 1, 13.4% (25/186) in attack 2, 10.6%
(15/142) in attack 3, and 14.5% (16/110) in attack 4.Triptan-related adverse events
A total of 12.3% (27/219) of subjects had at least 1
triptan-related AE, with 10.6% (23/216), 9.1% (17/186),
7.7% (11/142), and 7.3% (8/110) of subjects experiencing
them in attacks 1, 2, 3, and 4, respectively. Chest dis-
comfort was reported 32 times by a total of 6 subjects
(2.7%); 5 subjects had 30 mild events, and the sixth had
1 mild and 1 moderate event. These events were de-
scribed variously by the study investigators as chest
tightness, noncardiac; chest tightness after injection,
noncardiac; sensation of chest heaviness after injection,
noncardiac; and pressure sensation, chest, noncardiac.Discussion
This open-label extension study was conducted to evalu-
ate the efficacy, tolerability, and safety of DFN-11 in the
acute treatment of multiple migraine attacks in adults
with episodic migraine. At 2 h postdose, pain-free rates
ranged from 57.6% to 66.3%, pain relief response was
81.7% to 88.4%, and absence of the MBS ranged from
69.0% to 77.7% in the first 4 attacks treated with
DFN-11. Freedom from migraine associated symptoms
at 2 h ranged 78.1% to 86.5% for nausea, 72.3% to 77.5%
for photophobia, and 73.6% to 77.5% for phonophobia.
DFN-11 had a good tolerability profile, with a predict-
able but low incidence of TEAEs (ie, injection site reac-
tions) that were mostly mild, and a very low incidence of
triptan sensations (all considered noncardiac). These
findings show that DFN-11 was consistently effective,
tolerable, and safe in the acute treatment of multiple
migraine attacks over an 8-week period.
With the caveat that comparing efficacy results from
studies with different study populations and methodolo-
gies can be misleading, the magnitude of multiple-attack
response to DFN-11 appears to be roughly comparable
to the 6 mg SC dose of sumatriptan in published reports.
For example, an 18-month open-label study of the 6 mg
SC dose reported 2-h response rates of 67.0% for
pain-free and approximately 72% for pain relief [16]. A
trial evaluating sumatriptan SC 6 mg across 455 at-
tacks in 100 consecutive patients found that 84% of
subjects had pain relief at 2 h postdose [17]. In the
current study of the effects of DFN-11 across 4 at-
tacks, the range of 2-h pain-free rates was narrow
and slightly lower (approximately 58–66%), but the
range of pain relief responses was considerably higher
(approximately 82–88%).
The results of this study confirm and extend the
known safety profile of DFN-11. As expected, the overall
rate of AEs was low, and only 1 subject experienced
severe TEAEs. The most frequently reported TEAEs
overall (injection site swelling and pain), as well as those
associated with triptans (chest discomfort), decreased in
incidence across the 4 treated attacks. Slightly more than
one quarter (27.4%) of subjects treated with DFN-11 had
at least 1 injection site reaction, which is less than half
the rate reported with a 6-mg dose autoinjector (59%)
[12] and about one third the incidence in a
placebo-controlled study (79%) pooling data from 4
attacks [18]. The rate of injection site TEAEs may be
related to the DFN-11 lower dose of active drug, dilute
solution, and thin needle — the last of which has been
shown to reduce pain and increase patient adherence
[19]. Chest discomfort affected only 2.7% of subjects
treated with DFN-11, and 5 of the 6 affected subjects
reported only mild symptoms. Accounting for differ-
ences that might be expected due to the lower dose of
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sumatriptan (3 mg vs 6 mg), this still represents a reduc-
tion from rates observed in earlier multiple-attacks stud-
ies of the 6 mg SC dose of sumatriptan. For example, in
a previous study over a median of 25 months, 41% of
subjects treated with a 6 mg dose of SC sumatriptan ex-
perienced chest symptoms in all attacks, and 39% had
them in some attacks, leading 10% of subjects to discon-
tinue sumatriptan [20]. In the placebo-controlled study
of 4 attacks [18], 15.6% of subjects treated with the 6 mg
dose of SC sumatriptan reported chest symptoms, an
83% increase versus DFN-11.
Limitations of this study include the open-label design
and a possible selection bias for responders during the
open-label period. Also, the study did not assess
consistency of response within each individual. Despite
these, the size of the study and consistency of response
across 4 attacks suggest that DFN-11 will provide pre-
dictable migraine relief in clinical practice. In addition,
the low incidence of TEAEs that generally decreased
across the 4 attacks may increase patient confidence in
positive results, encourage patient adherence to profes-
sional recommendations (eg, treating at the first sign of
migraine pain) and, ultimately, contribute to better effi-
cacy outcomes in clinical practice.
Conclusions
DFN-11 was consistently effective, tolerable, and safe in
the acute treatment of multiple migraine attacks over an
8-week period. The responses to DFN-11 at 2 h postdose
on migraine pain freedom, pain relief, and associated
symptoms (including the most bothersome) endpoints
were substantial, and their range across attacks was nar-
row. TEAEs were predictable and mostly mild, with a
very low incidence of triptan sensations. These findings
underscore the potential of DFN-11 as an effective and
safe SC sumatriptan option for the acute treatment of
migraine.
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